Drug Trial Radar · NCT07865130
Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jun 2033
Study completion Jun 2033
Sponsor
- Lead sponsor
- Bożenna Dembowska BagińskaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ryvu Therapeutics SA
- First posted
- Oct 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will determine the safety and tolerability of RVU120 as a single agent and in combination with the mTOR inhibitor everolimus in children with recurrent or progressive G3 or G4 medulloblastoma and provide preliminary data regarding the efficacy of this treatment approach.
Conditions
- Medulloblastoma Recurrent
- Medulloblastoma
Interventions
RVU120Drug
Experimantal - RVU120
Everolimus (Afinitor) tabletsDrug
RVU120 + everolimus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and nature of AEs, SAEs and DLTs according to CTCAE v5.0 in RVU120 monotherapy and combination therapy with everolimusTime frame: From Day1 to 30 days after last dose
- MTD and/or RP2D of RVU120 as a single agent and in combination with everolimusTime frame: During Cycle 1 (DLT evaluation period; each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Instytut "Pomnik - Centrum Zdrowia Dziecka", Centrum Wsparcia Pediatrycznych Badań Klinicznych
Warsaw, Masovian Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.